ACLS guide line
ACLS algorithm cardiac arrest shockable non-shockable rhythm
| Shockable | Non-Shockable |
|---|---|
| Ventricular Fibrillation (VF) | Asystole |
| Pulseless Ventricular Tachycardia (pVT) | Pulseless Electrical Activity (PEA) |

| Drug | Dose | Indication |
|---|---|---|
| Epinephrine | 1 mg IV/IO q 3–5 min | All cardiac arrest rhythms |
| Amiodarone | 300 mg IV, then 150 mg | VF/pVT refractory to defibrillation |
| Lidocaine | Alternative to amiodarone | VF/pVT |
| Magnesium sulfate | 1–2 g IV | Torsades de pointes / hypomagnesemia |
| Atropine | 0.5–1 mg IV | Symptomatic bradycardia |
| Vasopressin | 40 units IV | Alternative vasopressor (less commonly used now) |
Epinephrine note: A trial of 8,014 patients showed slightly higher 30-day survival with epinephrine vs. placebo (3.2% vs 2.4%, P=0.02), but no difference in favorable neurologic outcome (2.2% vs 1.9%). — Fuster and Hurst's The Heart, 15th Ed.
| Monitor | Value | Significance |
|---|---|---|
| End-tidal CO₂ (ETCO₂) | 15–20 mmHg during CPR | Normal = 35–45 mmHg |
| ETCO₂ at ROSC | Jumps to >35 mmHg | Reliable indicator of ROSC |
| ETCO₂ <10 mmHg after >20 min | Poor prognostic marker | May indicate futility |
| H's | T's |
|---|---|
| Hypovolemia | Tension pneumothorax |
| Hypoxia | Tamponade (cardiac) |
| Hydrogen ion (acidosis) | Toxins |
| Hypo/Hyperkalemia | Thrombosis (pulmonary — PE) |
| Hypothermia | Thrombosis (coronary — ACS) |